Difference between revisions of "How I Treat"
Jump to navigation
Jump to search
| Line 44: | Line 44: | ||
*'''2021:''' Lew et al. [https://ashpublications.org/blood/article-abstract/138/5/361/475780/How-I-treat-chronic-lymphocytic-leukemia-after How I treat chronic lymphocytic leukemia after venetoclax] | *'''2021:''' Lew et al. [https://ashpublications.org/blood/article-abstract/138/5/361/475780/How-I-treat-chronic-lymphocytic-leukemia-after How I treat chronic lymphocytic leukemia after venetoclax] | ||
*'''2019:''' Stephens & Byrd. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6428663/ How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia] | *'''2019:''' Stephens & Byrd. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6428663/ How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia] | ||
| − | *'''2018:''' Brown | + | *'''2018:''' Brown. [https://doi.org/10.1182/blood-2017-08-764712 How I treat CLL patients with ibrutinib] [https://pubmed.ncbi.nlm.nih.gov/29255067/ PubMed] |
===[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]=== | ===[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]=== | ||
Revision as of 11:13, 7 September 2023
The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered high-level expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles.
Articles are presented by condition, in reverse chronological order. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
Note: this page is currently under construction.
Malignant hematology
Myeloid neoplasms
Acute lymphoblastic leukemia (ALL)
- 2023: Si Lim et al. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults PubMed
- 2023: Kopmar & Cassaday How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia PubMed
- 2020: Aldoss & Douer. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia PubMed
- 2020: Aldoss & Forman. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy PubMed
- 2019: Ravandi How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia PubMed
- 2015: Curran & Stock. How I treat acute lymphoblastic leukemia in older adolescents and young adults PubMed
- 2015: Frey & Luger. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia PubMed
Acute myeloid leukemia (AML)
- 2023: Biederstädt & Rezvani How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy PubMed
- 2021: Falini et al. How I diagnose and treat NPM1-mutated AML PubMed
- 2020: DeWolf & Tallman How I treat relapsed or refractory AML PubMed
- 2020: DiNardo & Wei. How I treat acute myeloid leukemia in the era of new drugs PubMed
- 2016: Ofran et al. How I treat acute myeloid leukemia presenting with preexisting comorbidities PubMed
- 2015: Röllig & Ehninger. How I treat hyperleukocytosis in acute myeloid leukemia PubMed
- 2014: Ossenkoppele & Löwenberg. How I treat the older patient with acute myeloid leukemia PubMed
- 2011: Bakst et al. How I treat extramedullary acute myeloid leukemia PubMed
Chronic myeloid leukemia (CML)
Myelodysplastic syndrome (MDS)
- 2019: Santini How I treat MDS after hypomethylating agent failure
- 2013: Sekeres & Cutler How we treat higher-risk myelodysplastic syndromes PubMed
- 2013: Fenaux & Adès How we treat lower-risk myelodysplastic syndromes
Polycythemia vera (PV)
- 2014: Vannucchi How I treat polycythemia vera PubMed
Lymphoid neoplasms
Adult T-cell leukemia-lymphoma (ATLL)
- 2021: Cook & Phillips How I treat adult T-cell leukemia/lymphoma PubMed
Chronic lymphocytic leukemia (CLL/SLL)
- 2021: Lew et al. How I treat chronic lymphocytic leukemia after venetoclax
- 2019: Stephens & Byrd. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
- 2018: Brown. How I treat CLL patients with ibrutinib PubMed
Cutaneous T-cell lymphoma (CTCL)
- 2019: Shinohara & Shustov How I treat primary cutaneous CD30 + lymphoproliferative disorders
Hodgkin lymphoma
- 2021: Epperla & Herrera How I incorporate novel agents into the treatment of classical Hodgkin lymphoma
- 2020: Eichenauer & Engert How I treat nodular lymphocyte-predominant Hodgkin Lymphoma
Diffuse large B-cell lymphoma (DLBCL)
- 2023: Lugtenburg & Mutsaers How I treat older patients with DLBCL in the frontline setting PubMed
Follicular lymphoma (FL)
- 2019: Casulo & Barr How I treat early-relapsing follicular lymphoma PubMed
NK- and T-cell lymphoma
- 2013: Tse & Kwong How I treat NK/T-cell lymphomas PubMed
Waldenström macroglobulinemia (WM)
- 2019: Dimopoulos & Kastritis. How I treat Waldenström macroglobulinemia PubMed
Plasma cell dyscrasias
Light-chain (AL) amyloidosis
- 2022: Palladini & Merlini How I treat AL amyloidosis
Multiple myeloma
- 2023: van de Donk How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells
- 2022: Zamagni et al. How I treat high-risk multiple myeloma
- 2022: Kastritis et al. How I treat relapsed multiple myeloma
- 2022: Vaxman & Gertz How I approach smoldering multiple myeloma